

Hsin-Tzu Liu

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5565152/hsin-tzu-liu-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,217
citations

20
h-index

30
g-index

30
ext. papers

1,338
ext. citations

3.7
avg. IF

4.56
L-index

#	Paper	IF	Citations
30	Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. <i>European Urology</i> , 2009 , 56, 700-6	10.2	138
29	Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. <i>BJU International</i> , 2009 , 104, 1476-81	5.6	99
28	Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. <i>Journal of Urology</i> , 2008 , 179, 2270-4	2.5	97
27	Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. <i>Urology</i> , 2008 , 72, 104-8; discussion 108	1.6	84
26	Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. <i>BJU International</i> , 2009 , 103, 1668-72	5.6	82
25	Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. <i>BJU International</i> , 2010 , 106, 1681-5	5.6	81
24	Pilot study of liposome-encapsulated onabotulinumtoxin A for patients with overactive bladder: a single-center study. <i>European Urology</i> , 2014 , 65, 1117-24	10.2	78
23	Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. <i>Urology</i> , 2012 , 80, 225.e13-8	1.6	75
22	Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. <i>BJU International</i> , 2008 , 102, 1440-4	5.6	52
21	Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. <i>Neurourology and Urodynamics</i> , 2011 , 30, 1525-9	2.3	49
20	Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. <i>Neurourology and Urodynamics</i> , 2009 , 28, 78-81	2.3	48
19	Increased urine and serum nerve growth factor levels in interstitial cystitis suggest chronic inflammation is involved in the pathogenesis of disease. <i>PLoS ONE</i> , 2012 , 7, e44687	3.7	46
18	Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. <i>Journal of the Formosan Medical Association</i> , 2010 , 109, 862-78	3.2	41
17	Urinary nerve growth factor in women with overactive bladder syndrome. <i>BJU International</i> , 2011 , 107, 799-803	5.6	39
16	Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015 , 7, 102-7	1.9	38
15	Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2010 , 2, 88-94	1.9	26
14	Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. <i>PLoS ONE</i> , 2014 , 9, e91609	3.7	23

13	Increased expression of transient receptor potential vanilloid subfamily 1 in the bladder predicts the response to intravesical instillations of resiniferatoxin in patients with refractory idiopathic detrusor overactivity. <i>BJU International</i> , 2007 , 100, 1086-90	5.6	23
12	Increased serum adipokines implicate chronic inflammation in the pathogenesis of overactive bladder syndrome refractory to antimuscarinic therapy. <i>PLoS ONE</i> , 2013 , 8, e76706	3.7	21
11	Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. <i>BJU International</i> , 2009 , 104, 1158-62	5.6	21
10	Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings. <i>Neurourology and Urodynamics</i> , 2015 , 34, 757-62	2.3	14
9	Overactive bladder changes with time: a 5-year longitudinal followup of changes in overactive bladder symptoms, urodynamic studies and urinary nerve growth factor levels. <i>Journal of Urology</i> , 2014 , 192, 458-63	2.5	11
8	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011 , 3, 2-9	1.9	8
7	Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2015 , 10, e0134803	3.7	8
6	Lower Levels of Urinary Nerve Growth Factor Might Predict Recurrent Urinary Tract Infections in Women. <i>International Neurourology Journal</i> , 2016 , 20, 33-9	2.6	7
5	Identification of the alternative splice products encoded by the human protein phosphatase inhibitor-1 gene. <i>Biochemical and Biophysical Research Communications</i> , 2002 , 291, 1293-6	3.4	4
4	Letter to the editor: backbone 1H, 15N, and 13C resonance assignments of inhibitor-1--a protein inhibitor of protein phosphatase-1. <i>Journal of Biomolecular NMR</i> , 2001 , 21, 287-8	3	3
3	Expressions of urothelial functional proteins in idiopathic detrusor overactivity patients refractory to antimuscarinic therapy with different urodynamic characteristics. <i>Neurourology and Urodynamics</i> , 2017 , 36, 1313-1319	2.3	1
2	Molecular mechanisms and translational medicine application of Oroxylin A in microRNA 155-5p targeting IRF2BP2-NFAT1 axis in sepsis induced lung injury. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, PO3-9-21	0	
1	Pharmacogenetic study of methadone treatment for heroin addiction: associations between drug-metabolizing gene polymorphisms and treatment efficacy. <i>Pharmacogenetics and Genomics</i> , 2022 , 32, 31-38	1.9	